Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.

Article  CAS  PubMed  Google Scholar 

Frühbeck G, Díez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med. 2004;350:308–9.

Article  PubMed  Google Scholar 

Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–7.

Article  CAS  PubMed  Google Scholar 

Adriaenssens AE, Svendsen B, Lam BY, Yeo GS, Holst JJ, Reimann F, et al. Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia. 2016;59:2156–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Holst B, Cygankiewicz A, Jensen TH, Ankersen M, Schwartz TW. High constitutive signaling of the ghrelin receptor–identification of a potent inverse agonist. Mol Endocrinol. 2003;17:2201–10.

Article  CAS  PubMed  Google Scholar 

Dass NB, Munonyara M, Bassil AK, Hervieu GJ, Osbourne S, Corcoran S, et al. Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin. Neuroscience. 2003;120:443–53.

Article  CAS  PubMed  Google Scholar 

Rodríguez A, Gómez-Ambrosi J, Catalán V, Gil MJ, Becerril S, Sáinz N, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes. 2009;33:541–52.

Article  Google Scholar 

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–9.

Article  CAS  PubMed  Google Scholar 

Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–13.

Article  PubMed  Google Scholar 

Pfluger PT, Kirchner H, Gunnel S, Schrott B, Perez-Tilve D, Fu S, et al. Simultaneous deletion of ghrelin and its receptor increases motor activity and energy expenditure. Am J Physiol Gastrointest Liver Physiol. 2008;294:G610–8.

Article  CAS  PubMed  Google Scholar 

St-Pierre DH, Karelis AD, Cianflone K, Conus F, Mignault D, Rabasa-Lhoret R, et al. Relationship between ghrelin and energy expenditure in healthy young women. J Clin Endocrinol Metab. 2004;89:5993–7.

Article  CAS  PubMed  Google Scholar 

Mani BK, Uchida A, Lee Y, Osborne-Lawrence S, Charron MJ, Unger RH, et al. Hypoglycemic effect of combined ghrelin and glucagon receptor blockade. Diabetes. 2017;66:1847–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao TJ, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci USA. 2010;107:7467–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Massadi O, Nogueiras R, Dieguez C, Girault JA. Ghrelin and food reward. Neuropharmacology. 2019;148:131–8.

Article  CAS  PubMed  Google Scholar 

Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E. The role of the central ghrelin system in reward from food and chemical drugs. Mol Cell Endocrinol. 2011;340:80–7.

Article  CAS  PubMed  Google Scholar 

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001;50:707–9.

Article  PubMed  Google Scholar 

Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 2003;52:2546–53.

Article  PubMed  Google Scholar 

Schöfl C, Horn R, Schill T, Schlosser HW, Müller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:4607–10.

Article  PubMed  Google Scholar 

Ezquerro S, Mocha F, Frühbeck G, Guzmán-Ruiz R, Valentí V, Mugueta C, et al. Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab. 2019;104:21–37.

PubMed  Google Scholar 

Marchesini G, Pagotto U, Bugianesi E, De Iasio R, Manini R, Vanni E, et al. Low ghrelin concentrations in nonalcoholic fatty liver disease are related to insulin resistance. J Clin Endocrinol Metab. 2003;88:5674–9.

Article  CAS  PubMed  Google Scholar 

Krause A, Sillard R, Kleemeier B, Kluver E, Maronde E, Conejo-Garcia JR, et al. Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver. Protein Sci. 2003;12:143–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, et al. LEAP2 is an endogenous antagonist of the ghrelin receptor. Cell Metab. 2018;27(461–9):e6.

Google Scholar 

Howard A, Townes C, Milona P, Nile CJ, Michailidis G, Hall J. Expression and functional analyses of liver expressed antimicrobial peptide-2 (LEAP-2) variant forms in human tissues. Cell Immunol. 2010;261:128–33.

Article  CAS  PubMed  Google Scholar 

Francisco V, Tovar S, Conde J, Pino J, Mera A, Lago F, et al. Levels of the novel endogenous antagonist of ghrelin receptor, liver-enriched antimicrobial peptide-2, in patients with rheumatoid arthritis. Nutrients. 2020;12:1006. https://doi.org/10.3390/nu12041006

Sakai K, Shiomi K, Mochizuki H, Islam MN, Nabekura H, Tanida R, et al. Human liver-expressed antimicrobial peptide 2 elevation in the cerebrospinal fluid in bacterial meningitis. Brain Behav. 2021;11:e02111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mani BK, Puzziferri N, He Z, Rodriguez JA, Osborne-Lawrence S, Metzger NP, et al. LEAP2 changes with body mass and food intake in humans and mice. J Clin Invest. 2019;129:3909–23.

Article  PubMed  PubMed Central  Google Scholar 

M’Kadmi C, Cabral A, Barrile F, Giribaldi J, Cantel S, Damian M, et al. N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor. J Med Chem. 2019;62:965–73.

Article  PubMed  Google Scholar 

Islam MN, Mita Y, Maruyama K, Tanida R, Zhang W, Sakoda H, et al. Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents. J Endocrinol. 2020;244:13–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lugilde J, Casado S, Beiroa D, Cuñarro J, Garcia-Lavandeira M, Álvarez CV, et al. LEAP-2 counteracts ghrelin-induced food Intake in a nutrient, growth hormone and age independent manner. Cells. 2022;11:324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ezquerro S, Tuero C, Becerril S, Valentí V, Moncada R, Landecho MF, et al. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease. Eur J Endocrinol. 2023;188:564–77.

PubMed  Google Scholar 

Çakar S, Arslan N, Ateş M, Sayin O, Akyaz O, Tatar Arik T, et al. Serum LEAP-2 as a potential biomarker for hepatic steatosis in adolescents with obesity and MASLD: a cross-sectional study. Diagnostics (Basel). 2025;15:2816. https://doi.org/10.3390/diagnostics15212816

Gahete MD, Rincón-Fernández D, Villa-Osaba A, Hormaechea-Agulla D, Ibáñez-Costa A, Martínez-Fuentes AJ, et al. Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight. J Endocrinol. 2014;220:R1-24.

Article  CAS